Pharmacokinetic study of rolapitant + midazolam in volunteers.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2018
Price : $35 *
At a glance
- Drugs Rolapitant (Primary) ; Midazolam
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics
- 13 Nov 2018 Results of this and other two phase I studies published in the Journal of Clinical Pharmacology.
- 08 Jul 2013 New trial record
- 28 Jun 2013 Results presented at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) International Symposium, according to a TESARO media release.